Revvity, Inc.

revvity.com

What Do They Do?

Sells laboratory instruments, testing supplies and software for life-sciences researchers and the diagnostics market.

How Do They Make Money?

Customers buy instruments, reagents and some software, generally paying within 30 to 60 days. Subscriptions, cloud services, laboratory services and training bring in revenue over the periods those services are provided.

revenue

Segment	Share	Revenue	How money arrives
Product Sold outright	84% FY2022: 80%		Sold outright
Service Recurring	16% FY2022: 20%		Recurring

Who Are Their Customers?

Most customers buy through the company’s specialized sales teams; distributors serve regions without direct sales coverage. Customers include life-sciences researchers, pharmaceutical and biotechnology companies, contract research organizations, and academic and government institutions.

Do Revenues Turn Into Profits?

Yes. It kept 8 cents of every revenue dollar as net income in FY2025 and turned 18 cents into free cash flow.

Operating income, FY2025

12% of revenue

▲ +3% vs FY2024 ($346.7M, 13%)

Net income, FY2025

8% of revenue

▼ −11% vs FY2024 ($270.4M, 10%)

Free cash flow, FY2025

18% of revenue

▼ −6% vs FY2024 ($541.7M, 20%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jul 5, 2026

Revenue: ▲ +1%; vs $720.3M in Q2 FY2025
Net income: ▼ −4%; vs $53.9M in Q2 FY2025

Product share of revenue vs 84.8% in Q2 FY2025

Aug 4, 2026 Agreed to sell China Immunodiagnostics and raised 2026 guidance China IDX represented approximately 6% of fiscal year 2025 revenue; the sale is expected to close by the end of 2027.

Shrinking. Revenue fell 25% in 4 years, from $3.8B in FY2021 to $2.9B in FY2025, about 7% a year.

Applied-market offerings The older report grouped life-sciences research with environmental, food and industrial applied markets; the latest describes Life Sciences and Diagnostics as its two segments, with Life Sciences focused on researchers.

Revenue over time

Product Service

$5B$2.5B$0

FY2021 FY2022 FY2023 FY2024 FY2025

Comments